Cyclooxygenase-1–selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus

Preterm delivery is the leading cause of neonatal mortality and contributes significantly to infant morbidity. Classical cyclooxygenase (COX) inhibitors, such as indomethacin, which inhibit both COX-1 and COX-2, are effective for delaying premature labor, but their use is limited by serious complications to the fetus and neonate, including adverse effects on the ductus arteriosus (DA). Using isoform-selective inhibitors, we characterized the roles of the COX isoforms in the initiation of labor and the regulation of fetal and neonatal DA closure in mice. Chronic inhibition of COX-2 during pregnancy (gestation days 15–18) significantly increased neonatal mortality by preventing closure of the DA after birth, whereas acute COX-2 inhibition near the end of term (gestation day 18) constricted the fetal DA. In contrast, the inhibition of COX-1 during pregnancy lacked these prenatal and postnatal adverse effects on the DA and effectively delayed the initiation of full-term labor and LPS-induced preterm labor. These findings suggest that premature fetal DA closure or neonatal patent DA observed following indomethacin tocolysis in women may result from the inhibition of COX-2. Therefore, COX-1–selective inhibitors may provide effective treatment to delay preterm labor with fewer adverse effects on fetal or neonatal health than nonselective or COX-2–selective inhibitors.

Preterm delivery is the leading cause of perinatal mortality and contributes to delayed physical and cognitive development in children. Although a significant number of preterm cases would benefit from delaying labor, there is considerable debate on the safety and efficacy of currently available medications for the maintenance of tocolysis (1–3). Prostaglandin (PG) synthase (cyclooxygenase, or COX) inhibitors, also known as nonsteroidal anti-inflammatory drugs (NSAIDs), represent one of the several classes of tocolytics effective for delaying labor in the short term, but their usefulness is limited, in part, by adverse effects on the fetus (4, 5). One of the major adverse effects of NSAIDs is on the ductus arteriosus (DA). The DA is a muscular artery that connects the main pulmonary artery and the aorta. PGs in the fetal circulation are thought to maintain dilation of the DA in utero. The dilated DA in the fetus diverts the pulmonary circulation away from the high-resistance vascular beds of the uninflated lungs. After birth, the transition to pulmonary respiration is accompanied by the constriction and functional closure of the DA. The failure of the DA to close after birth, termed patent DA, is a neonatal complication often associated with premature births.

Indomethacin, the dual COX isoform inhibitor most commonly used to delay premature labor, is associated with two paradoxical effects on the DA. Indomethacin is reported to induce constriction of the fetal DA in as many as 50% of cases following maternal administration (5–7). In both humans and rodents, acute maternal administration of indomethacin induces constriction of the fetal DA by inhibiting the synthesis of PGs important for DA dilation in utero (6, 8, 9). In utero constriction of the DA impedes blood flow through the vessel and may result in pulmonary hypertension or heart failure in the fetus (5, 10). Alternatively, maternal administration of indomethacin during pregnancy can also increase the risk for development of patent DA in infants after birth (4, 11, 12). Patent DA adversely affects neonatal health by contributing to respiratory distress, congestive heart failure, and conditions resulting from tissue ischemia (13).

The COX inhibitors that have been used for tocolysis, such as indomethacin, inhibit activity of the two known isoforms, COX-1 and COX-2. Recently, medications selective for inhibiting the COX-2 isoform have been suggested as novel tocolytics with fewer adverse effects than result from dual COX isoform inhibitors (2, 14, 15). However, we recently reported that in mice, the expression of COX-2 was essential for eliminating a patent DA phenotype (16). Herein, we show that in mice, selective inhibition of COX-2 results in fetal DA constriction or postnatal DA patency, depending on the dosing regimen, and does not affect the normal onset of labor. Furthermore, selective inhibition of COX-1 does not cause fetal DA constriction or neonatal patent DA and is effective for delaying the initiation of labor.

Acute inhibition of COX-2, but not COX-1, induces premature constriction of the fetal DA. To determine the relative contribution of the COX isoforms in maintaining DA dilation in utero, we analyzed the fetal mouse DA following a single maternal dose of selective inhibitors of COX-1 or COX-2 on gestation day 18 (Figure 1a). As expected, histological analysis demonstrated that the DA constricted in wild-type fetuses following indomethacin administration (Figure 1c), whereas the DA remained dilated following vehicle administration (Figure 1b). Similar to the effects of indomethacin, the COX-2–selective inhibitors celecoxib (Figure 1d) and SC-236 (Figure 1e) also induced DA constriction. In contrast to indomethacin and the COX-2 inhibitors, the COX-1–selective inhibitor SC-560 (22), at the equivalent dose (Figure 1f) as well as a 2.5-fold higher dose (Figure 1g), failed to induce constriction of the fetal DA.

Figure 1

Fetal DA constriction following acute isoform-selective or nonselective COX inhibition on gestation day 18. (a) Incidence (no. constricted/no. analyzed) of fetal DA constriction following treatment with COX inhibitors indomethacin (indo), celecoxib (cel), SC-236 (236), and SC-560 (560). *Significantly different from incidence in vehicle-treated mice. P < 0.01, n ≥ 6. (b–g) Histology of mouse DA after a single inhibitor treatment. (b) Vehicle. (c) Dual COX isoform inhibitor indomethacin, 20 mg/kg. (d) COX-2–selective inhibitor celecoxib, 20 mg/kg. (e) COX-2–selective inhibitor SC-236, 20 mg/kg. (f) COX-1–selective inhibitor SC-560, 20 mg/kg. (g) SC-560, 50 mg/kg. Ao, descending aorta. Scale bar, 100 μm.

Chronic inhibition of COX-2 during gestation does not produce fetal DA constriction. In contrast to DA constriction induced by a single dose of COX-2 inhibitor SC-236 on gestation day 18 (Figure 1e), administration of SC-236 earlier in gestation (gestation day 15) did not produce an observable effect on the fetal DA (compare Figure 2a with Figure 2b). Furthermore, DA constriction was not induced by SC-236 treatment on gestation day 17 (data not shown) or gestation day 18 (Figure 2c) in the fetuses of dams that were treated with the COX-2 inhibitor beginning on gestation day 15. Therefore, fetal DA constriction was not observed following chronic inhibition of COX-2 on gestation days 15–18.

Figure 2

Chronic inhibition of COX-2 during gestation does not result in fetal DA constriction. Analysis of fetal DA on day 15 of gestation, 4 hours following administration of (a) vehicle or (b) COX-2–selective inhibitor SC-236. (c) Chronic administration (on gestation days 15–18) of SC-236 and fetal analysis 4 hours after the dose on gestation day 18. Scale bar, 100 μm.

Chronic inhibition of COX-2 during gestation produces neonatal patent DA. With the observation that fetal DA constriction did not occur following chronic inhibition of COX-2 during pregnancy (Figure 2), we examined the effect of this maternal dosing regimen on closure of the neonatal DA. The DA was completely occluded at 5 hours after birth in all wild-type neonates treated with vehicle during gestation (Figure 3a). In contrast, chronic maternal administration (on gestation days 15–18) of SC-236 resulted in a postnatal patent DA incidence of 59% in neonates wild-type for both COX-1 and COX-2 (Table 1 and Figure 3c). Similar to the effects of SC-236, maternal administration of celecoxib on gestation days 15–18 resulted in a 53% incidence of patent DA in wild-type neonates at 5 hours after birth. Furthermore, the extent to which COX-2 inhibition increased patent DA incidence was influenced by the COX-1 genotype. For neonates heterozygous- or homozygous-null for COX-1 and wild-type for COX-2, the COX-2 inhibitor (SC-236) treatment resulted in a patent DA inci-dence of 70% and 100%, respectively (Table 1). There was no significant increase in patent DA incidence in COX-1^+/+/COX-2^–/– neonates following COX-2 inhibitor (SC-236) treatment (Table 1), suggesting that SC-236 treatment did not inhibit COX-1. These data demonstrate that chronic administration of COX-2–selective inhibitors during gestation significantly increased the incidence of patent DA after birth.

Figure 3

Neonatal patent DA following chronic COX-2 inhibition. Maternal administration of (a) vehicle, (b) COX-1–selective inhibitor SC-560, or (c–f) COX-2–selective inhibitor SC-236 on gestation days 15–18. Histological DA analysis of wild-type neonates sacrificed 5 hours after birth is shown in a–c. d–f shows postmortem DA analysis of wild-type neonates that died (d) between 5 and 24 hours after birth, (e) between 24 and 48 hours after birth, or (f) were sacrificed after 48 hours for comparison. Scale bar, 100 μm.

Table 1

Neonatal patent DA incidence following isoform-selective COX inhibition

In contrast to the COX-2–selective inhibitors, chronic administration (on gestation days 15–18) of the COX-1–selective inhibitor SC-560 failed to induce patent DA in neonates wild-type for both COX-1 and COX-2 (Figure 3b). The COX-1–selective inhibitor also failed to induce patent DA in all neonates wild-type for COX-2, irrespective of the COX-1 genotype (Table 1). We previously reported that for COX-2–deficient neonates, reduction of the gene copy number of COX-1 significantly increases patent DA incidence (16). In the present study, SC-560 treatment significantly increased the patent DA incidence in neonates deficient in COX-2. One-hundred percent of the neonates deficient in COX-2 and wild-type for COX-1 showed patent DA following COX-1 inhibitor treatment, compared with the 35% incidence observed in neonates of this genotype following vehicle treatment (Table 1). Therefore, in COX-2–deficient neonates, the chronic inhibition of COX-1 during gestation eliminated COX-1–dependent DA closure; however, for all neonates that expressed COX-2, there was no increase in patent DA incidence following COX-1 inhibitor treatment.

Maternal administration of SC-560 inhibits the activity of COX-1 in the fetus. COX-2–selective and nonselective COX inhibitors readily cross the placenta and enter the fetal circulation (23–25). However, transfer of the COX-1–selective inhibitor SC-560 to the fetal circulation following maternal administration has not previously been reported. Therefore, to demonstrate that SC-560 crossed the placenta and entered the fetus following maternal administration, we measured PGE₂ synthesis in fetal skin, which is a rich source of COX-1 (16). As shown in Table 2, maternal administration of SC-560 on gestation days 15–18 reduced the fetal skin concentration of PGE₂ synthesized from endogenous arachidonic acid by more than 95%. Because this observed reduction in fetal PGE₂ may result from inhibiting the synthesis of PGE₂ that is supplied to the fetus from maternal tissue, the inhibition of fetal COX-1 activity was confirmed by measuring PGE₂ levels after the exogenous addition of arachidonic acid to fetal skin homogenates. Maternal administration of SC-560 on gestation days 15–18 inhibited the synthesis of PGE₂ formed from exogenous arachidonic acid by more than 95% (Table 2). Therefore, the maternal administration of SC-560 effectively inhibited the activity of COX-1 expressed in the fetus. In contrast to COX-1–selective inhibition, maternal administration of the COX-2–selective inhibitor SC-236 did not significantly reduce PGE₂ levels in fetal skin homogenates (Table 2). Thus, COX-2 does not significantly contribute to PGE₂ synthesis in fetal skin, and at the doses used, SC-236 does not inhibit COX-1.

Table 2

Maternal administration of SC-560 inhibits the activity of COX-1 expressed in the fetus

Chronic inhibition of COX-2 during gestation increases neonatal mortality. We previously reported that patent DA resulting from the genetic deficiency of COX-2 increases neonatal mortality (16). Because COX-2 inhibitor administration also increased the incidence of patent DA (Table 1), neonatal mortality was examined following COX-2 inhibition during gestation. More than 98% of the wild-type neonates, from dams treated with SC-236 on gestation days 15–18, were born alive after a normal gestation length. However, 71% of these neonates died during the first 48 hours following birth, compared with 2% of neonates from vehicle-treated dams. In the mice that survived beyond 48 hours following COX-2 inhibitor treatment during gestation, there was no further increase in mortality when observed to the age of weaning. In neonates deficient in COX-1 and wild-type for COX-2, COX-2 inhibitor treatment resulted in a 100% incidence of neonatal mortality. Therefore, chronic inhibition of COX-2 during gestation significantly increased neonatal mortality.

Postmortem analysis was performed to identify pathologies responsible for the observed mortality in neonates born to dams chronically treated with a COX-2 inhibitor (on gestation days 15–18). Lungs, heart, kidney, liver, pancreas, spleen, thymus, intestine, and stomach of neonates from dams treated with SC-236 were indistinguishable in histological analyses from vehicle-treated controls. The only pathology observed in neonates following chronic COX-2 inhibitor treatment during gestation was patent DA.

Considerable variability in the duration of neonatal survival was observed following chronic treatment with SC-236 during gestation. To determine whether variability in DA closure could explain the differences in survival duration, the extent of DA closure was compared with survival duration for neonates that died at different times during the first 48 hours after birth. Histological analysis of the DA from neonates that died during the first 24 hours after birth shows no evidence of closure (Figure 3d). Partial closure of the DA with narrowing of the DA lumen was evident in neonates that died from 24 to 48 hours after birth (Figure 3e), as compared with the completely occluded DA of neonates that survived longer than 48 hours and were sacrificed (Figure 3f). Therefore, partial closure of the DA correlated with prolonged survival up to 48 hours, whereas the complete failure of DA closure correlated with mortality during the first 24 hours after birth.

Selective inhibition of COX-1 during pregnancy delays the onset of full-term and preterm labor. In humans, the therapeutic usefulness of dual COX isoform inhibitors for prolonging gestation is limited, in part, by the adverse effects of fetal DA constriction or postnatal patent DA (4–7, 11, 12). After finding that these adverse effects in wild-type mice did not occur with SC-560, we examined the effectiveness of this COX-1–selective inhibitor for delaying the initiation of full-term labor in mice. Treatment with SC-560 beginning on gestation day 15 resulted in an average gestation length of 20.7 days, whereas the average gestation length of vehicle-treated mice was 18.7 days (Table 3). Although the COX-1 inhibitor prolonged the length of gestation, the duration of labor was not significantly different from that of vehicle-treated mice (data not shown). In contrast to COX-1 inhibition, neither of the COX-2–selective inhibitors, celecoxib and SC-236, significantly affected the length of gestation (Table 3).

Table 3

Inhibition of COX-1 delays the initiation of full-term and preterm labor

The tocolytic effects of COX-1–selective inhibition were also analyzed using a model of preterm labor induced by LPS (20, 21). Intraperitoneal injection of LPS to six pregnant mice on gestation day 15 initiated preterm labor within 24 hours in all six, and resulted in a 100% incidence of fetal death. However, when eight mice were treated with SC-560 on gestation days 14–17, none of them littered during the first 24 hours after LPS treatment. SC-560 treatment significantly prolonged the average gestation length of LPS-treated mice (Table 3) and increased the number of litters that were carried to term (six of eight). SC-560 treatment also significantly increased overall litter survival from zero to 72% following LPS treatment. These findings indicate that inhibition of COX-1 effectively delays the initiation of full-term and preterm labor in mice.

Thromboxane receptor agonists induce neonatal closure of the DA. The deficiency of both COX-1 and COX-2 in mice results in a 100% incidence of neonatal patent DA (16) and provides a model for identifying prostanoids with activity for initiating closure of the DA after birth. Following treatment of COX-1^–/–/COX-2^–/– neonates with vasoactive prostanoids or stable prostanoid analogues, the DA was examined histologically for evidence of DA closure (Table 4). Neither PGF_2α nor sulprostone (an EP1/EP3 agonist), prostanoids previously shown to produce constriction in the vasculature (26, 27), induced closure of the DA when administered to COX-1^–/–/COX-2^–/– neonates. The stable prostacyclin analogue, carbaprostacyclin, also failed to induce closure of the DA. Although the treatment of neonatal mice with PGE₂ dilates the DA after birth (28), mice deficient in the EP₄ type PGE₂ receptor show increased patent DA incidence (28, 29), suggesting a role for the EP₄ receptor in DA closure. Therefore we treated COX-1^–/–/COX-2^–/– neonates with the EP₄-selective agonist ONO-AE1-329 (30) to determine the potential for EP₄-selective activation to induce DA closure. The EP₄ receptor agonist not only failed to induce DA closure in COX-1^–/–/COX-2^–/– neonates, but also prevented closure in wild-type neonates (Figure 4a), similar to the reported effect of PGE₂ (28, 31). In contrast to the other prostanoids, the PGH₂ analogue U46619 (32) and the thromboxane A₂ analogue I-BOP (33), two structurally distinct thromboxane receptor agonists, both induced DA closure (Table 4 and Figure 4b) that was histologically indistinguishable from that of vehicle-treated wild-type neonates at 5 hours after birth (Figure 4a).

Figure 4

Prostanoid analogues modulate neonatal DA closure. (a) COX-1^+/+/COX-2^+/+ neonates treated with vehicle (top row) or EP₄-selective agonist ONO-AE1-329 (bottom row). (b) COX-1^–/–/COX-2^–/– neonates treated with vehicle (top row) or PGH₂ analogue U46619 (bottom row). Scale bar, 100 μm.

Table 4

Effects of exogenous prostanoids on neonatal DA closure

Despite the availability of several classes of pharmacological treatments to delay preterm delivery, premature birth remains the leading cause of neonatal mortality and morbidity. Currently available tocolytics, including COX inhibitors such as indomethacin, have been shown to be effective in delaying labor in the short term (48–72 hours), but their efficacy for the long-term tocolytic maintenance necessary to significantly improve neonatal health has not been demonstrated (1–3, 34). Therefore there is considerable interest in identifying novel medications for safe and effective tocolysis.

The tocolytic effects of nonselective COX inhibitors in humans may result from inhibiting COX-1 and/or COX-2. In mice, the initiation of labor results from the reduction of serum progesterone following PGF_2α-induced lysis of the corpus luteum (35). In COX-1–deficient mice, the reduced synthesis of PGF_2α delays the initiation of labor (36), whereas the effects of COX-2 deficiency on the initiation of labor are not known because of female infertility (37, 38). We studied the functions of the two COX isoforms in the initiation of full-term labor in mice by comparing tocolytic effects of selective inhibition of either COX-1 or COX-2. The treatment of pregnant mice with a selective inhibitor of COX-1 delayed the initiation of full-term labor, whereas COX-2–selective inhibitors produced no effect on gestation length (Table 3). Recently, COX-2 inhibition in mice has been shown to delay the initiation of LPS-induced preterm labor (20, 21). However, the present study indicates that COX-2–selective inhibition has adverse effects on the fetal or neonatal DA that may compromise neonatal health. With our findings that COX-1 inhibition did not produce these adverse effects and significantly delayed the initiation of full-term labor, we examined the tocolytic effectiveness of COX-1 inhibition on preterm labor induced by LPS. COX-1–selective inhibition prolonged the average gestation length following LPS treatment (Table 3), which significantly improved neonatal survival. Therefore, in mice, PG synthesis dependent on the activity of COX-1 contributes to the initiation of full-term labor and LPS-induced preterm labor.

COX inhibitors have been used for decades to delay preterm delivery, but their usefulness is limited, in part, by constriction of the fetal DA. Human and mouse fetuses are highly sensitive to the DA constrictor effects of indomethacin (6, 16), and recently, COX-2–selective inhibitors were shown to constrict the fetal DA in mice and sheep (23, 39). In the present study, we determined the DA-constricting effects of COX isoform–selective and –nonselective inhibition in the mouse fetus. When administered near the end of gestation, the COX-2–selective inhibitors SC-236 and celecoxib both induced fetal DA constriction similar to that resulting from indomethacin treatment (Figure 1). In contrast, the COX-1–selective inhibitor SC-560 failed to induce constriction of the fetal DA (Figure 1). Thus, in mice, the adverse effect of indomethacin-induced fetal DA constriction following acute maternal administration results from inhibiting the synthesis of PGs derived primarily via COX-2 rather than COX-1.

Recently, we and others described the failure of DA closure in neonatal mice deficient in both COX-1 and COX-2 (16, 39), and our studies provided the initial insight into the key role of COX-2 in the normal closure of the DA (16). In contrast to a report by Reese et al. (39), our findings (16) demonstrated that high levels of COX-2 were expressed in the smooth muscle cells of the DA during closure of the vessel after birth, suggesting that COX-2 expressed in the DA functions in the closure of the vessel. Because COX-2–selective inhibitors (and nonselective COX inhibitors) are known to cross the placenta (23–25), we hypothesized that following chronic maternal administration, COX-2–selective inhibitors may enter the fetal circulation and inhibit COX-2 expressed in the DA, thereby preventing normal closure in the neonate. In support of this hypothesis, our present findings indicate that in wild-type mice, chronic inhibition of COX-2, but not COX-1, significantly increased the incidence of patent DA following birth (Table 1).

In the present study, we observed that neonatal patent DA resulted from chronic inhibition of COX-2 during gestation, whereas acute inhibition of COX-2 late in gestation produced fetal DA constriction. The contrasting effects of COX-2 inhibition suggest opposing actions of different prostanoids on the regulation of DA tone. PGE₂ in the fetal circulation, supplied in part by the placenta, maintains a dilated DA by attenuating DA muscle contraction (9, 40). This suggests that constriction of the fetal DA following acute COX-2 inhibition late in gestation results from inhibiting the synthesis of PGE₂ supplied to the DA by the placenta. Our previous findings demonstrate that the DA, unlike the adjacent aorta or pulmonary artery, expresses a significant level of COX-2 following birth (16), which we propose is responsible for the synthesis of prostanoids that contribute to DA muscle contraction. This is consistent with our finding that stable analogues of PGH₂ and thromboxane A₂ both induced DA constriction in the COX-1^–/–/COX-2^–/– neonates, which without intervention show a 100% incidence of patent DA (Table 4 and Figure 4). Previous studies in sheep determined that thromboxane A₂ is not synthesized by DA tissue (41, 42), and these data in combination with our present findings suggest a predominant role for the known vasoconstrictor PGH₂ (43) as the PG contributing to DA closure. Therefore, chronic administration of COX-2 inhibitors during gestation may sufficiently inhibit the synthesis of PGH₂ produced by COX-2 in the DA to attenuate muscle contraction and result in patent DA.

The incidence and clinical severity of patent DA is significantly increased in infants born to women treated with indomethacin (4, 11, 12). Recently, indomethacin-induced ovine fetal DA constriction was shown to damage DA smooth muscle and make the DA refractory to postnatal DA constriction (44). This suggests that fetal DA constriction may contribute to postnatal patent DA. However, we observed that acute COX-2 inhibitor treatment on gestation day 15 did not constrict the fetal DA (Figure 2), suggesting that similar to reported effects of indomethacin (7, 8), incomplete development of DA contractile function in preterm fetuses makes the DA resistant to COX-2 inhibitor–induced constriction. Furthermore, chronic administration of the COX-2 inhibitor beginning on gestation day 15 produced resistance to SC-236–induced constriction on gestation day 18 (Figure 2). Therefore, our data indicate that fetal DA constriction does not appear to be required for the neonatal patent DA that we observed following COX-2 inhibitor treatment during gestation.

Although our findings indicate that patent DA did not result from the inhibition of COX-1 in wild-type mice, a role for COX-1 in postnatal DA closure was identified by combining pharmacological inhibition with genetic inactivation. The spontaneous patent DA incidence in COX-2–deficient mice (35%) was increased to 100% following COX-1 inhibitor treatment during pregnancy (Table 1). The COX-1 inhibitor produced patent DA only in mice genetically deficient in COX-2, whereas patent DA resulting from COX-2 inhibition did not require the genetic inactivation of COX-1. Thus, COX-1 plays only a compensatory role, and COX-2 is the isoform primarily responsible for DA closure.

Chronic inhibition of COX-2 during gestation also significantly increased neonatal mortality during the first 48 hours following birth. Analysis of the pups that died demonstrated that the DA had failed to close, whereas patent DA was not observed in neonates that survived beyond 48 hours after birth (Figure 3). In addition to the regulation of DA tone, PGs, particularly PGI₂, are also believed to be important for dilation of the pulmonary vasculature following birth (45, 46). It is possible that by inhibiting PGI₂ synthesis, COX inhibitors may increase pulmonary vascular resistance, which may impede normal postnatal DA closure. However, analysis of the lungs of neonates that died following COX-2 inhibitor treatment during gestation failed to find histological evidence of pulmonary hypertension such as pulmonary vascular wall remodeling. Furthermore, a stable PGI₂ analogue was not effective for inducing postnatal closure of the DA (Table 4 and Figure 4), suggesting that pulmonary hypertension was not responsible for the observed patent DA following COX-2–selective inhibition. Although other unidentified pathologies may occur, the correlation of patent DA incidence and severity with neonatal mortality and survival duration, respectively, suggests that patent DA directly contributed to COX-2 inhibitor–induced neonatal mortality.

In the current study we have demonstrated that COX-1–selective inhibition, but not COX-2–selective inhibition, effectively delays labor without adverse DA effects in the fetus or neonate. Recently, Reese et al. described the effects of COX-2 inhibitor treatment during pregnancy on the length of full-term gestation and neonatal survival in mice (39). Similar to our current findings, the report by Reese et al. showed that the normal gestation length is not prolonged by a dose of celecoxib selective for the inhibition of COX-2 (10 mg/kg); however, gestation length was prolonged by treatment with celecoxib at 600 mg/kg, a dose that the authors suggested may inhibit both COX-1 and COX-2 (39). Our current findings of prolonged gestation following COX-1–selective inhibition suggest that the prolonged gestation described by Reese et al. following treatment with high doses of celecoxib may have resulted primarily from inhibiting COX-1. Prolonged gestation in mice, resulting from either COX-1 deficiency (17, 36, 39) or from celecoxib doses that may also inhibit COX-1 (39), is associated with reduced pup survival. However, Reese et al. also reported increased pup mortality with doses of celecoxib (200 mg/kg) that did not significantly prolong gestation (39), although the cause or causes of mortality were not identified. Our current findings of patent DA and resulting neonatal mortality following chronic COX-2 inhibition during pregnancy suggest that the increased pup mortality observed by Reese et al. following celecoxib treatment may have resulted in part from patent DA. Overall, the results to date support our conclusion that COX-1–selective inhibition may provide a novel method of delaying labor.

Premature birth significantly increases the incidence of patent DA, suggesting that premature infants may be especially susceptible to medications that prevent or delay closure of the DA after birth. Because women in premature labor are the target population for tocolysis, particular caution is warranted for novel tocolytics with the potential to attenuate DA closure in the newborn. Recently, numerous reports have suggested that COX-2–selective inhibitors may be effective for delaying preterm birth in women (2, 14, 15, 20, 47, 48). Our previous genetic findings, together with the present pharmacological studies, indicate that in mice, COX-2 activity in the fetus or neonate is important for closure of the DA after birth. If the mechanisms of DA closure are conserved between species, the use of COX-2–selective inhibitors as tocolytics in women may impede normal closure of the DA after birth. Furthermore, our findings suggest that COX-1–selective inhibitors may provide effective tocolysis without the adverse DA effects of nonselective or COX-2–selective inhibitors.

We thank Ono Pharmaceutical Co., Osaka, Japan, for the generous gift of ONO-AE1-329.

Conflict of interest: No conflict of interest has been declared.

Nonstandard abbreviations used: prostaglandin (PG); cyclooxygenase (COX); nonsteroidal anti-inflammatory drugs (NSAIDs); ductus arteriosus (DA).

1. Bernal, A. Overview of current research in parturition. Exp Physiol 2001. 86:213-222.
   View this article via: PubMed CrossRef Google Scholar
2. Vause, S, Johnston, T. Management of preterm labour. Arch Dis Child Fetal Neonatal Ed 2000. 83:F79-F85.
   View this article via: PubMed CrossRef Google Scholar
3. Norwitz, ER, Robinson, JN, Challis, JR. The control of labor. N Engl J Med 1999. 341:660-666.
   View this article via: PubMed CrossRef Google Scholar
4. Norton, ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology 1997. 56:282-292.
   View this article via: PubMed CrossRef Google Scholar
5. Moise, KJJ, et al. Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med 1988. 319:327-331.
   View this article via: PubMed Google Scholar
6. Vermillion, ST, Scardo, JA, Lashus, AG, Wiles, HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997. 177:256-259.
   View this article via: PubMed CrossRef Google Scholar
7. Moise, KJJ. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993. 168:1350-1353.
   View this article via: PubMed Google Scholar
8. Momma, K, Takao, A. In vivo constriction of the ductus arteriosus by nonsteroidal antiinflammatory drugs in near-term and preterm fetal rats. Pediatr Res 1987. 22:567-572.
   View this article via: PubMed CrossRef Google Scholar
9. Smith, GCS. The pharmacology of the ductus arteriosus. Pharmacol Rev 1998. 50:35-58.
   View this article via: PubMed Google Scholar
10. Eronen, M. The hemodynamic effects of antenatal indomethacin and a beta-sympathomimetic agent on the fetus and the newborn: a randomized study. Pediatr Res 1993. 33:615-619.
    View this article via: PubMed Google Scholar
11. Hammerman, C, et al. Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Pediatrics 1998. 102:E561-E564.
12. Norton, ME, Merrill, J, Cooper, BA, Kuller, JA, Clyman, RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993. 329:1602-1607.
    View this article via: PubMed CrossRef Google Scholar
13. Hammerman, C, Kaplan, M. Patent ductus arteriousus in the premature neonate: current concepts in pharmacological management. Paediatr Drugs 1999. 1:81-92.
    View this article via: PubMed CrossRef Google Scholar
14. Sadovsky, Y, et al. Effective diminution of amniotic prostaglandin production by selective inhibitors of cyclooxygenase type 2. Am J Obstet Gynecol 2000. 182:370-376.
    View this article via: PubMed CrossRef Google Scholar
15. Vane, JR, Botting, RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998. 47(Suppl. 2):S78-S87.
    View this article via: PubMed CrossRef Google Scholar
16. Loftin, CD, et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA 2001. 98:1059-1064.
    View this article via: PubMed CrossRef Google Scholar
17. Langenbach, R, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995. 83:483-492.
    View this article via: PubMed CrossRef Google Scholar
18. Morham, SG, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995. 83:473-482.
    View this article via: PubMed CrossRef Google Scholar
19. Penning, TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997. 40:1347-1365.
    View this article via: PubMed CrossRef Google Scholar
20. Sakai, M, et al. Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery. Mol Hum Reprod 2001. 6:595-602.
21. Gross, G, et al. Inhibition of cyclooxygenase-2 prevents inflammation-mediated preterm labor in the mouse. Amer J Physiol Regul Integr Comp Physiol 2000. 278:R1415-R1423.
    View this article via: PubMed Google Scholar
22. Smith, CJ, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998. 95:13313-13318.
    View this article via: PubMed CrossRef Google Scholar
23. Takahashi, Y, et al. Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Amer J Physiol Regul Integr Comp Physiol 2000. 278:R1496-R1505.
    View this article via: PubMed Google Scholar
24. Moise, KJJ, et al. Placental transfer of indomethacin in the human pregnancy. Am J Obstet Gynecol 1990. 162:549-554.
    View this article via: PubMed Google Scholar
25. Kramer, WB, et al. Placental transfer of sulindac and its active sulfide metabolite in humans. Am J Obstet Gynecol 1995. 172:886-890.
    View this article via: PubMed CrossRef Google Scholar
26. Smith, GC, McGrath, JC. Contractile effects of prostanoids on fetal rabbit ductus arteriosus. J Cardiovasc Pharmacol 1995. 25:113-118.
    View this article via: PubMed Google Scholar
27. Lock, JE, Olley, PM, Coceani, F. Direct pulmonary vascular responses to prostaglandins in the conscious newborn lamb. Am J Physiol 1980. 238:H631-H638.
    View this article via: PubMed Google Scholar
28. Nguyen, M, et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature 1997. 390:78-81.
    View this article via: PubMed CrossRef Google Scholar
29. Segi, E, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998. 246:7-12.
    View this article via: PubMed CrossRef Google Scholar
30. Suzawa, T, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000. 141:1554-1559.
    View this article via: PubMed CrossRef Google Scholar
31. Takizawa, T, et al. Dilating effect of prostaglandin on the constricted ductus arteriosus in newborn rats. J Toxicol Sci 1995. 20:29-32.
    View this article via: PubMed Google Scholar
32. Kattelman, EJ, Venton, DL, Le Breton, GC. Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res 1986. 41:471-481.
    View this article via: PubMed CrossRef Google Scholar
33. Morinelli, TA, et al. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp Ther 1989. 251:557-562.
    View this article via: PubMed Google Scholar
34. Thornton, S, Vatish, M, Slater, D. Oxytocin antagonists: clinical and scientific considerations. Exp Physiol 2001. 86:297-302.
    View this article via: PubMed CrossRef Google Scholar
35. Sugimoto, Y, et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997. 277:681-683.
    View this article via: PubMed CrossRef Google Scholar
36. Gross, GA, et al. Opposing actions of prostaglandins and oxytocin determine the onset of murine labor. Proc Natl Acad Sci USA 1998. 95:11875-11879.
    View this article via: PubMed CrossRef Google Scholar
37. Lim, H, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997. 91:197-208.
    View this article via: PubMed CrossRef Google Scholar
38. Dinchuk, JE, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995. 378:406-409.
    View this article via: PubMed CrossRef Google Scholar
39. Reese, J, et al. Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci USA 2000. 97:9759-9764.
    View this article via: PubMed CrossRef Google Scholar
40. Thorburn, GD. The placenta, PGE2 and parturition. Early Hum Dev 1992. 29:63-73.
    View this article via: PubMed CrossRef Google Scholar
41. Pace-Asciak, CR, Rangaraj, G. Application of prostaglandin-profiling techniques to study the release of prostaglandins from the fetal lamb ductus arteriosus. Biochim Biophys Acta 1983. 750:330-333.
    View this article via: PubMed Google Scholar
42. Pace-Asciak, CR, Rangaraj, G. Release of prostaglandins from intact fetal lamb ductus arteriosus. Can J Biochem Cell Biol 1983. 61:240-247.
    View this article via: PubMed Google Scholar
43. Lin, L, Balazy, M, Pagano, PJ, Nasjletti, A. Expression of prostaglandin H2-mediated mechanism of vascular contraction in hypertensive rats. Relation to lipoxygenase and prostacyclin synthase activities. Circ Res 1994. 74:197-205.
    View this article via: PubMed Google Scholar
44. Clyman, RI, et al. In utero remodeling of the fetal lamb ductus arteriosus: the role of antenatal indomethacin and avascular zone thickness on vasa vasorum proliferation, neointima formation, and cell death. Circulation 2001. 103:1806-1812.
    View this article via: PubMed Google Scholar
45. Shaul, PW. Regulation of vasodilator synthesis during lung development. Early Hum Dev 1999. 54:271-294.
    View this article via: PubMed CrossRef Google Scholar
46. Davidge, ST. Prostaglandin H synthase and vascular function. Circ Res 2001. 89:650-660.
    View this article via: PubMed CrossRef Google Scholar
47. Sawdy, RJ, Slater, DM, Dennes, WJB, Sullivan, MHF, Bennett, PR. The roles of the cyclo-oxygenases types one and two in prostaglandin synthesis in human fetal membranes at term. Placenta 2000. 21:54-57.
    View this article via: PubMed CrossRef Google Scholar
48. Yousif, MH, Thulesius, O. Tocolytic effect of the cyclooxygenase-2 inhibitor, meloxicam: studies on uterine contractions in the rat. J Pharm Pharmacol 1998. 50:681-685.
    View this article via: PubMed Google Scholar